article · Applied Organometallic Chemistry
Researchers have synthesised and characterised four new lanthanide complexes using lanthanum, cerium, neodymium, and dysprosium combined with a novel Schiff base ligand derived from 2-aminobenzothiazole and coumarin. Analytical, spectroscopic, and theoretical assessments confirmed the chemical structures of these compounds. Biological evaluations compared the complexes against standard agents including cisplatin, gentamicin, ampicillin, and ascorbic acid to measure their anticancer, antibacterial, and antioxidant properties. Across all tests, biological activity followed a consistent order, with the cerium complex demonstrating the highest efficacy, followed by neodymium, dysprosium, lanthanum, and finally the uncoordinated ligand. Molecular docking simulations reinforced these experimental observations, showing that the cerium complex achieved the strongest negative binding energies against specific protein targets associated with liver cancer and Bacillus subtilis bacterial infections.
Developing new therapeutic compounds is crucial for addressing major healthcare challenges such as cancer and drug-resistant bacterial infections. By combining lanthanide metals with organic molecules, scientists can discover potent multifunctional candidates. This research highlights cerium and neodymium complexes as particularly effective agents that simultaneously display anticancer, antibacterial, and antioxidant capabilities, providing a foundation for future therapeutic design.
This work could eventually enable the creation of new therapeutic drugs for pharmaceutical developers targeting liver cancer and bacterial infections. However, the findings are currently at an early laboratory stage, limited to chemical synthesis, standard in vitro screening, and molecular docking simulations. Substantial preclinical validation, toxicology assessments, and in vivo trials will be required before any potential real-world pharmaceutical application can be pursued.
AI-generated from the published abstract. Always read the original work before citing.
Four novel lanthanide La (III), Ce (III), Nd (III), and Dy (III) complexes with (Z)‐4‐(benzo[d]thiazol‐2‐ylamino)‐3‐((benzo[d]thiazol‐2‐ylimino)methyl)‐2H‐chromen‐2‐one (L) were prepared and characterized. The novel compounds' structural compositions were elucidated by the application of analytical and spectroscopic methodologies. From physical and chemical measurements, the general formula for the [LnL Cl 3 ]2H 2 O complexes (C1‐C4) was proposed, which was proven by theoretical measurements. Using cisplatin, gentamicin, ampicillin, and ascorbic acid as standards, the compound's anticancer, antibacterial, and antioxidant qualities were assessed, and activities followed the order: Ce (III)L(C2) > Nd (III)L(C3) > Dy (III)L(C4) > La (III)L(C1) > L where the Ce (III) complexes exhibited the highest activity followed by Nd (III) complexes. Molecular docking studies were performed using the MOA2022 software to identify putative binding mechanisms for the methionine adenosyl‐transferases in liver cancer (PDB ID: 5A19) and the most active site of the Bacillus subtilis receptor (PDB ID: 5e6k), where the strength of the interaction increases with the negative binding energy L ˂ [LaL Cl 3 ] ˂ [DyL Cl 3 ] ˂ [NdL Cl 3 ] ˂ [CeL Cl 3 ].
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1002/aoc.7622
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
